Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Chapman

Showing results (301-310 of 320) with videos related to

Pageof 32
Sort By:
The Lancet. Diabetes & Endocrinology|October 5, 2019
Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statementRobert A Hegele, Jan Borén, Henry N Ginsberg, et al.
European Heart Journal|March 27, 2018
New prospects for PCSK9 inhibition?Ulf Landmesser, M John Chapman, Jane K Stock, et al.
European Heart Journal|October 19, 2017
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemiaUlf Landmesser, M John Chapman, Jane K Stock, et al.
European Heart Journal|September 2, 2021
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis SocietyHenry N Ginsberg, Chris J Packard, M John Chapman, et al.
European Heart Journal|April 27, 2017
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus PanelBrian A Ference, Henry N Ginsberg, Ian Graham, et al.
Clinical Chemistry and Laboratory Medicine|December 20, 2019
Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLMMichel R Langlois, Børge G Nordestgaard, Anne Langsted, et al.
Atherosclerosis|January 14, 2020
Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLMBørge G Nordestgaard, Michel R Langlois, Anne Langsted, et al.
The Lancet. Diabetes & Endocrinology|June 2, 2016
Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia PanelRaul D Santos, Samuel S Gidding, Robert A Hegele, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2014
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and managementRobert A Hegele, Henry N Ginsberg, M John Chapman, et al.
European Heart Journal|February 20, 2015
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and ManagementErik S Stroes, Paul D Thompson, Alberto Corsini, et al.
Pageof 32

Showing results (301-310 of 320) with videos related to

Sort By:
Pageof 32
The Lancet. Diabetes & Endocrinology|October 5, 2019
Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statementRobert A Hegele, Jan Borén, Henry N Ginsberg, et al.
European Heart Journal|March 27, 2018
New prospects for PCSK9 inhibition?Ulf Landmesser, M John Chapman, Jane K Stock, et al.
European Heart Journal|October 19, 2017
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemiaUlf Landmesser, M John Chapman, Jane K Stock, et al.
European Heart Journal|September 2, 2021
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis SocietyHenry N Ginsberg, Chris J Packard, M John Chapman, et al.
European Heart Journal|April 27, 2017
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus PanelBrian A Ference, Henry N Ginsberg, Ian Graham, et al.
Clinical Chemistry and Laboratory Medicine|December 20, 2019
Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLMMichel R Langlois, Børge G Nordestgaard, Anne Langsted, et al.
Atherosclerosis|January 14, 2020
Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLMBørge G Nordestgaard, Michel R Langlois, Anne Langsted, et al.
The Lancet. Diabetes & Endocrinology|June 2, 2016
Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia PanelRaul D Santos, Samuel S Gidding, Robert A Hegele, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2014
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and managementRobert A Hegele, Henry N Ginsberg, M John Chapman, et al.
European Heart Journal|February 20, 2015
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and ManagementErik S Stroes, Paul D Thompson, Alberto Corsini, et al.
Pageof 32